HHS Orders End to Medical Gender Transitions for Minors

The U.S. Department of Health and Human Services has issued a directive prohibiting healthcare providers from administering puberty blockers, cross-sex hormones, and gender-related surgeries to minors.

The decision follows a review confirming these interventions are unsupported by robust scientific evidence and carry significant risks.

HHS concluded that prior guidelines promoting these treatments were ideologically driven and medically unsound. Providers are now barred from using discredited protocols that enabled irreversible changes in children without adequate long-term data.

This Shouldn’t Be Considered Controversial

The directive redirects care toward psychological and psychiatric support—aligning with updated standards in the UK, Sweden, and Finland, where similar interventions have already been scaled back or banned.

Puberty blockers have been found ineffective for treating gender dysphoria and may cause permanent harm.

Cross-sex hormones and surgeries carry serious, lifelong consequences, including infertility, loss of sexual function, and increased health risks. These are not rare side effects—they are common outcomes.

For years, the medical establishment framed these treatments as “affirming care,” ignoring the lack of controlled studies and downplaying the damage.

Children were placed on irreversible paths under the guise of informed consent, often before they could fully understand the implications.

The HHS directive marks a shift toward evidence-based policy. It rejects medical experimentation on minors and acknowledges the failure of a lost, spineless system that prioritized ideology over science.

This is not progress. It is merely a correction. Long overdue.